361 related articles for article (PubMed ID: 34576327)
1. Whence CRIPTO: The Reemergence of an Oncofetal Factor in 'Wounds' That Fail to Heal.
Freeman DW; Rodrigues Sousa E; Karkampouna S; Zoni E; Gray PC; Salomon DS; Kruithof-de Julio M; Spike BT
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576327
[TBL] [Abstract][Full Text] [Related]
2. Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.
Adkins HB; Bianco C; Schiffer SG; Rayhorn P; Zafari M; Cheung AE; Orozco O; Olson D; De Luca A; Chen LL; Miatkowski K; Benjamin C; Normanno N; Williams KP; Jarpe M; LePage D; Salomon D; Sanicola M
J Clin Invest; 2003 Aug; 112(4):575-87. PubMed ID: 12925698
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and Cellular Analysis Reveals Ligand Binding Specificities, a Molecular Basis for Ligand Recognition, and Membrane Association-dependent Activities of Cripto-1 and Cryptic.
Aykul S; Parenti A; Chu KY; Reske J; Floer M; Ralston A; Martinez-Hackert E
J Biol Chem; 2017 Mar; 292(10):4138-4151. PubMed ID: 28126904
[TBL] [Abstract][Full Text] [Related]
4. Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.
Gray PC; Shani G; Aung K; Kelber J; Vale W
Mol Cell Biol; 2006 Dec; 26(24):9268-78. PubMed ID: 17030617
[TBL] [Abstract][Full Text] [Related]
5. Nodal-dependent Cripto signaling promotes cardiomyogenesis and redirects the neural fate of embryonic stem cells.
Parisi S; D'Andrea D; Lago CT; Adamson ED; Persico MG; Minchiotti G
J Cell Biol; 2003 Oct; 163(2):303-14. PubMed ID: 14581455
[TBL] [Abstract][Full Text] [Related]
6. GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth.
Shani G; Fischer WH; Justice NJ; Kelber JA; Vale W; Gray PC
Mol Cell Biol; 2008 Jan; 28(2):666-77. PubMed ID: 17991893
[TBL] [Abstract][Full Text] [Related]
7. Cripto favors chondrocyte hypertrophy via TGF-β SMAD1/5 signaling during development of osteoarthritis.
Garcia de Vinuesa A; Sanchez-Duffhues G; Blaney-Davidson E; van Caam A; Lodder K; Ramos Y; Kloppenburg M; Meulenbelt I; van der Kraan P; Goumans MJ; Ten Dijke P
J Pathol; 2021 Nov; 255(3):330-342. PubMed ID: 34357595
[TBL] [Abstract][Full Text] [Related]
8. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.
Kelber JA; Panopoulos AD; Shani G; Booker EC; Belmonte JC; Vale WW; Gray PC
Oncogene; 2009 Jun; 28(24):2324-36. PubMed ID: 19421146
[TBL] [Abstract][Full Text] [Related]
9. Role of Cripto-1 in stem cell maintenance and malignant progression.
Bianco C; Rangel MC; Castro NP; Nagaoka T; Rollman K; Gonzales M; Salomon DS
Am J Pathol; 2010 Aug; 177(2):532-40. PubMed ID: 20616345
[TBL] [Abstract][Full Text] [Related]
10. Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers.
Sandomenico A; Ruvo M
Curr Med Chem; 2019; 26(11):1994-2050. PubMed ID: 30207211
[TBL] [Abstract][Full Text] [Related]
11. A Multidisciplinary Review of the Roles of Cripto in the Scientific Literature Through a Bibliometric Analysis of its Biological Roles.
Rodrigues Sousa E; Zoni E; Karkampouna S; La Manna F; Gray PC; De Menna M; Kruithof-de Julio M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32517087
[TBL] [Abstract][Full Text] [Related]
12. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis.
Strizzi L; Bianco C; Normanno N; Salomon D
Oncogene; 2005 Aug; 24(37):5731-41. PubMed ID: 16123806
[TBL] [Abstract][Full Text] [Related]
13. The multifaceted role of the embryonic gene Cripto-1 in cancer, stem cells and epithelial-mesenchymal transition.
Klauzinska M; Castro NP; Rangel MC; Spike BT; Gray PC; Bertolette D; Cuttitta F; Salomon D
Semin Cancer Biol; 2014 Dec; 29():51-8. PubMed ID: 25153355
[TBL] [Abstract][Full Text] [Related]
14. Cripto-1 alters keratinocyte differentiation via blockade of transforming growth factor-beta1 signaling: role in skin carcinogenesis.
Shukla A; Ho Y; Liu X; Ryscavage A; Glick AB
Mol Cancer Res; 2008 Mar; 6(3):509-16. PubMed ID: 18337457
[TBL] [Abstract][Full Text] [Related]
15. Cell-type specific regulation of myostatin signaling.
Kemaladewi DU; de Gorter DJ; Aartsma-Rus A; van Ommen GJ; ten Dijke P; 't Hoen PA; Hoogaars WM
FASEB J; 2012 Apr; 26(4):1462-72. PubMed ID: 22202673
[TBL] [Abstract][Full Text] [Related]
16. Role of Cripto-1 during epithelial-to-mesenchymal transition in development and cancer.
Rangel MC; Karasawa H; Castro NP; Nagaoka T; Salomon DS; Bianco C
Am J Pathol; 2012 Jun; 180(6):2188-200. PubMed ID: 22542493
[TBL] [Abstract][Full Text] [Related]
17. Dual roles of Cripto as a ligand and coreceptor in the nodal signaling pathway.
Yan YT; Liu JJ; Luo Y; E C; Haltiwanger RS; Abate-Shen C; Shen MM
Mol Cell Biol; 2002 Jul; 22(13):4439-49. PubMed ID: 12052855
[TBL] [Abstract][Full Text] [Related]
18. Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.
Kelber JA; Shani G; Booker EC; Vale WW; Gray PC
J Biol Chem; 2008 Feb; 283(8):4490-500. PubMed ID: 18089557
[TBL] [Abstract][Full Text] [Related]
19. Targeting the embryonic gene Cripto-1 in cancer and beyond.
Bianco C; Salomon DS
Expert Opin Ther Pat; 2010 Dec; 20(12):1739-49. PubMed ID: 21073352
[TBL] [Abstract][Full Text] [Related]
20. Cripto: a tumor growth factor and more.
Adamson ED; Minchiotti G; Salomon DS
J Cell Physiol; 2002 Mar; 190(3):267-78. PubMed ID: 11857442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
